These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
616 related articles for article (PubMed ID: 23422194)
1. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194 [TBL] [Abstract][Full Text] [Related]
2. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride. Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682 [TBL] [Abstract][Full Text] [Related]
3. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Habib FK; Ross M; Tate R; Chisholm GD Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694 [TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. Stanczyk FZ; Azen CG; Pike MC J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436 [TBL] [Abstract][Full Text] [Related]
5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
6. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line. Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094 [TBL] [Abstract][Full Text] [Related]
7. Reversible long-term toxicity of epristeride in beagle dogs. Sun ZY; Feng J; Qi XD; Wu HY; Zheng WJ; Tu ZH Toxicol Appl Pharmacol; 1999 Jan; 154(2):145-52. PubMed ID: 9925798 [TBL] [Abstract][Full Text] [Related]
8. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518 [TBL] [Abstract][Full Text] [Related]
9. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. Geller J J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697 [TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710 [TBL] [Abstract][Full Text] [Related]
12. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. George FW Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585 [TBL] [Abstract][Full Text] [Related]
13. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Dadras SS; Cai X; Abasolo I; Wang Z Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry. Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165 [TBL] [Abstract][Full Text] [Related]
16. Development of a new gas chromatography-mass spectrometry (GC-MS) methodology for the evaluation of 5α-reductase activity. Amaral C; Cunha SC; Fernandes JO; Tavares da Silva E; Roleira FM; Teixeira N; Correia-da-Silva G Talanta; 2013 Mar; 107():154-61. PubMed ID: 23598206 [TBL] [Abstract][Full Text] [Related]
17. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride. Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076 [TBL] [Abstract][Full Text] [Related]
18. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer. Hsieh JT; Chen SC; Yu HJ; Chang HC Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276 [TBL] [Abstract][Full Text] [Related]
19. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433 [TBL] [Abstract][Full Text] [Related]
20. [Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats]. Wang XD; Jia Y; Cui YG; Wang XH; Tong JS; Ma DZ; Cai RF; Di FS Zhonghua Nan Ke Xue; 2005 Sep; 11(9):652-4. PubMed ID: 16209201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]